Janus Kinase Inhibitors for Alopecia Areata: A Narrative Review

    June 2023 in “ Indian journal of dermatology, venereology, and leprology ”
    Renee D. Haughton, Samantha M. Herbert, Antonio Ji‐Xu … Emanual Maverakis
    Studysummary This narrative review reports that Janus kinase inhibitors show promise as an effective treatment for alopecia areata, especially in patients who do not respond to conventional therapies, although further research on long-term use and topical application is needed.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on ijdvl.com →
    Discuss this study in the Community →

    Research cited in this study 20

    1. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022
    2. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    3. A Case of Atopic Dermatitis with Alopecia Universalis in a Patient Treated with Abrocitinib JAAD case reports · 2022
    4. Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2021
    5. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    6. Treatment of Severe Alopecia Areata with Baricitinib JAAD Case Reports · 2019
    7. Clinical Experiences on Alopecia Areata Treatment with Tofacitinib: A Study of 63 Patients Dermatologic Therapy · 2019
    8. Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata Journal of the European Academy of Dermatology and Venereology · 2018
    9. Topical Tofacitinib Solution for the Treatment of Alopecia Areata Affecting Eyelashes JAAD Case Reports · 2018
    10. Ruxolitinib for the Treatment of Severe Alopecia Areata Journal of the American Academy of Dermatology · 2018
    11. Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study International Journal of Dermatology · 2018
    12. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    13. Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata Journal of the American Academy of Dermatology · 2017
    14. Treatment of Alopecia Areata With Tofacitinib JAMA Dermatology · 2017
    15. Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring International Journal of Dermatology · 2017
    16. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    17. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    18. Topical Ruxolitinib for the Treatment of Alopecia Universalis JAMA dermatology · 2015
    19. Epidemiology and Burden of Alopecia Areata: A Systematic Review Clinical, Cosmetic and Investigational Dermatology · 2015
    20. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014

    Related research 1

    1. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018